CELC
Celcuity·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 1
Stock Price Surged Significantly
Consensus Rating "Strong Buy"
Ample Liquidity
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CELC
Celcuity Inc.
A clinical-stage biotechnology company focused on developing therapies for several cancers
16305 36th , Avenue North, Suite 100, Minneapolis, MN 55446
--
Celcuity Inc., is incorporated in Delaware. The company is a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of a variety of solid tumor indications. The Company's primary therapeutic candidate is gedatolisib, a potent, well-tolerated small molecule reversible inhibitor that, when administered intravenously, selectively targets all class I isomers of phosphatidyl inositol 3-kinase (PI3K) and mTORC1 and mTORC2, two mechanistic targets of rapamycin (mTOR). The mechanism of action and pharmacokinetic properties of Gedatolisib are very different from currently approved and under development therapies that target PI3K or mTOR alone or together.
Earnings Call
Q2/2025
Estimate EPS-0.85
Actual EPS-1.04
Estimate Revenue--
Actual Revenue0
Celcuity's Q2 2025 Earnings Call: Unpacking Contradictions in Data Timelines, Patient Population Insights, and Regulatory Readiness
Aug 15,2025 11:48
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
CELC has released its 2025 Q3 earnings. EPS was reported at -0.78, versus the expected -0.96, beating expectations. The chart below visualizes how CELC has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
